Sym021-02- An Exploratory, Open-Label, Multicenter Phase 1B Trial To Evaluate Safety And Efficacy Of Sym021 (Anti-Pd-1) In Combination With Either Sym022 (Anti-Lag-3) Or Sym023 (Anti-Tim-3) In Patients With Advanced Solid Tumor Malignancies
Posted Date: May 6, 2021
- Investigator: Davendra Sohal
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The main purpose of this study is to evaluate safety and efficacy in participant with small cell lung cancer, urothelial cancer and bladder cancer who have developed resistance to prior anti-PD1 or anti-PD-L1 therapy and in patient with cholangiocarcinoma who have received at least 1 line of standard of care therapy and have progressed on it.
Criteria:
Documented (Histologically Or Cytologically Proven) Unresectable, Locally Advanced, Or Metastatic Small Cell Lung Cancer, Urothelial Cancer, Endometrial Cancer, Or Cholangiocarcinoma, Ecog Ps Of 0 Or 1, Life Expectancy Of =3 Months, No Serious/Active/Uncontrolled Infection Or Medical Condition That May Interfere With Patients Safety Or Ability To Adhere To Study Treatment, No Central Nervous System (Cns) Malignancies, No Known Or Suspected Hypersensitivity To Any Of The Excipients Of Formulated Study Drug
Keywords:
Lung Cancer, Urothelial Cancer, Bladder Cancer
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com